Stockscreener 앱 받기
1.62
1.82%
-0.03
Inflarx N V 주식(IFRX)의 최신 뉴스
Geode Capital Management LLC Grows Stake in InflaRx (NASDAQ:IFRX) - Defense World
InflaRx To Reveal Next Month Its Late-Stage Interim Results Of Lead Drug In Painful Ulcer - RTTNews
InflaRx (NASDAQ:IFRX) Earns Overweight Rating from Analysts at Cantor Fitzgerald - Defense World
Cantor Fitzgerald Predicts InflaRx FY2025 Earnings - Defense World
InflaRx (IFRX) Projected to Post Quarterly Earnings on Wednesday - Defense World
What is InflaRx N.V (IFRX) Stock Return on Shareholders’ Capital? - Sete News
Checking in on InflaRx N.V (IFRX) after recent insiders movement - knoxdaily.com
InflaRx N.V (IFRX) Stock: The Story of a 52-Week Stock Range - investchronicle.com
InflaRx N.V (IFRX) is an excellent investment, but the stock is overvalued/undervalued right now - uspostnews.com
InflaRx to Report First Quarter 2025 Results on May 7, 2025 - GlobeNewswire
InflaRx, Pioneer in Anti-Inflammatory Therapeutics, Announces Q1 2025 Earnings Date - Stock Titan
Cantor Fitzgerald Initiates Coverage of InflaRx N.V. (IFRX) with Overweight Recommendation - MSN
Cantor Fitzgerald sets $10 target for Inflarx stock, cites catalysts By Investing.com - Investing.com South Africa
Biotech Shares Jump As Institutional Coverage Begins With Positive Outlook - The Globe and Mail
Cantor Fitzgerald sets $10 target for Inflarx stock, cites catalysts - Investing.com
Cantor Fitzgerald Initiates InflaRx at Overweight $10 Price Target - marketscreener.com
InflaRx (IFRX) Projected to Rise with Upcoming Phase 3 Data Rele - GuruFocus
InflaRx Approves Key Resolutions at Annual Shareholder Meeting - MSN
InflaRx launches public offering of shares and warrants - MSN
Commonwealth Equity Services LLC Has $275,000 Stock Holdings in InflaRx (NASDAQ:IFRX) - Defense World
InflaRx N.V. Announces 2025 Annual General Meeting Agenda - TipRanks
Raymond James Financial Inc. Purchases Shares of 638,092 InflaRx (NASDAQ:IFRX) - Defense World
Guggenheim Forecasts Strong Price Appreciation for InflaRx (NASDAQ:IFRX) Stock - Defense World
Guggenheim raises Inflarx stock target to $10, maintains Buy rating By Investing.com - Investing.com Australia
InflaRx price target raised to $10 from $7 at Guggenheim - TipRanks
InflaRx (IFRX) Loses -15.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Guggenheim raises Inflarx stock target to $10, maintains Buy rating - Investing.com India
HC Wainwright Reiterates “Buy” Rating for InflaRx (NASDAQ:IFRX) - Defense World
InflaRx N.V. Reports 2024 Results and Key Achievements - TipRanks
InflaRx NV reports results for the quarter ended December 31Earnings Summary - TradingView
InflaRx stock reiterated at Buy at H.C. Wainwright after EU drug approval - MSN
InflaRx reports Q EPS (EUR 0.78) vs (EUR 0.78) last year - TipRanks
InflaRx Reports 2024 Results and Outlines 2025 Milestones - TipRanks
InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones - GlobeNewswire
InflaRx 2024 Earnings Reveal Strong Cash Position and Major EU Drug Win - StockTitan
Short Interest in InflaRx (NASDAQ:IFRX) Grows By 46.2% - Defense World
InflaRx (IFRX) Projected to Post Earnings on Thursday - Defense World
InflaRX Presents Efficacy and Safety Data on Vilobelimab at AAD 2025 - Dermatology Times
InflaRx (NASDAQ:IFRX) Earns Buy Rating from HC Wainwright - Defense World
InflaRx announces presentation of multiple posters on utility of vilobelimab - TipRanks
InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting - GlobeNewswire
Can This Drug Transform Hidradenitis Suppurativa Treatment? New Data Shows 3x Better Results - StockTitan
InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting - GlobeNewswire
Can InflaRx's Vilobelimab Transform Treatment for These Rare Skin Diseases? - StockTitan
InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences - GlobeNewswire
InflaRx N.V. to Release Fourth Quarter 2024 Financial Results and Participate in Key Investor Conferences - Nasdaq
InflaRx Financial Results Coming March 20: What's Next for this Anti-Inflammatory Therapeutics Developer? - StockTitan
Short Interest in InflaRx (NASDAQ:IFRX) Decreases By 13.7% - MarketBeat
InflaRx Concludes $30 Million Public Offering - TipRanks
InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewswire
InflaRx commences offering of ordinary shares and pre-funded warrants - MSN
0.89%
0.81%
자본화:
|
볼륨(24시간):